Guidance

Mpox (monkeypox) vaccination recommendations

Recommendations for the use of pre- and post-exposure vaccination during an mpox incident.

From:
UK Health Security Agency
Published
20 May 2022
Last updated
26 August 2022 — See all updates

Applies to England

Documents

Recommendations for the use of pre and post exposure vaccination during an mpox incident

Ref: UKHSA gateway number GOV-13161

PDF, 422 KB, 23 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document includes information on:

  • pre-exposure vaccination for occupational exposure
  • post-exposure vaccination
  • vaccine prescribing and administration
  • consent and record forms
  • Imvanex® patient information leaflet

Further mpox guidance is also available, including information on case definitions and contact tracing.

Published 20 May 2022
Last updated 26 August 2022 + show all updates

  1. Added version 12, removed appendices 2 to 5.

  2. Updated to include the use of intradermal administration for pre and post-exposure use in healthy adults, limiting post-exposure vaccination to children under 5 and immunosuppressed individuals, during periods of limited supply, and further clarification on vaccine eligibility for occupational exposure.

  3. Updated guidance, version 10.

  4. Version 9: updated background and added a link to classification of contacts (appendix 6), along with advice for vaccination and follow-up.

  5. Updated appendix 6 to clarify recommendations for PEP after 14 days since last exposure.

  6. Updated guidance, version 7.

  7. Updated guidance, version 6.7.

  8. Added links to additional monkeypox guidance.

  9. First published.

Related content